



# Alzheimer's Disease: A Chronic Neurodegenerative Disorder and Leading Cause of Dementia

Charlotte Taylor<sup>1\*</sup>, William Thompson<sup>2</sup> and Mason Walker<sup>2</sup>

<sup>1</sup>Department of Psychology, University of Canterbury, New Zealand

<sup>2</sup>Department of Psychological Medicine, University of Otago, New Zealand

memory loss, and behavioral changes, Alzheimer's typically begins with subtle symptoms and progressively worsens

**Received:** 1-Sep-2024, Manuscript No: dementia-24-148267, **Editor assigned:** 03-Sep-2024, PreQC No: dementia-24-148267 (PQ), **Reviewed:** 18-Sep-2024, QC No: dementia-24-148267, **Revised:** 23-Sep-2024, Manuscript No: dementia-24-148267 (R), **Published:** 30-Sep-2024, DOI: 10.4172/dementia.1000242

**Citation:** Taylor C (2024) Alzheimer's Disease: A Chronic Neurodegenerative Disorder and Leading Cause of Dementia J Dement 8: 242.

## Keywords:

**Copyright:** © 2024 Taylor C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

## 4. Symptoms and stages of alzheimer's disease

Alzheimer's disease is a chronic neurodegenerative disorder characterized by a progressive decline in cognitive function, memory, and behavior. The disease is typically divided into three stages: early, middle, and late.

### Middle stage:

In the middle stage, cognitive decline is more pronounced. Memory loss is significant, and individuals may experience difficulties with language, judgment, and problem-solving. Personality changes and behavioral symptoms, such as apathy and depression, are common.

### Late stage:

In the late stage, cognitive decline is severe. Individuals may lose the ability to recognize family members and perform basic self-care tasks. Behavioral symptoms, such as aggression and wandering, are common.

## Diagnosis of alzheimer's disease

Diagnosis of Alzheimer's disease is typically based on a combination of clinical history, physical examination, and cognitive testing. The following are key components of the diagnostic process:

### Imaging and biomarkers:

Imaging techniques, such as MRI and PET scans, can help identify structural changes in the brain and the presence of amyloid plaques and neurofibrillary tangles. Biomarkers, such as amyloid-beta and tau protein levels in cerebrospinal fluid, can also be used for diagnosis.

## Current treatment approaches

### Pharmacological treatments:

Pharmacological treatments for Alzheimer's disease include cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (e.g., memantine). These medications aim to improve cognitive function and manage symptoms.

### Non-pharmacological interventions:

Non-pharmacological interventions include cognitive stimulation, physical exercise, and social engagement. These approaches aim to improve quality of life and potentially slow the progression of the disease.

## Challenges in alzheimer's disease management

Managing Alzheimer's disease presents several challenges, including the lack of effective disease-modifying therapies, the need for long-term care, and the impact of behavioral symptoms on quality of life. Research is ongoing to address these challenges.

## Research and future directions

### Emerging therapeutic strategies:

Emerging therapeutic strategies include gene therapy, immunotherapy, and stem cell-based approaches. These strategies aim to target the underlying pathology of Alzheimer's disease and potentially reverse or slow the progression of the disease.

### Preventive approaches:

Preventive approaches include lifestyle modifications, such as regular exercise, a healthy diet, and cognitive stimulation. These approaches aim to reduce the risk of developing Alzheimer's disease.

Alzheimer's disease is a complex disorder with a multifactorial etiology. Understanding the underlying mechanisms and developing effective treatments remain major challenges in the field. Continued research and clinical trials are essential for improving the lives of those affected by this disease.

## Results and Discussion

### Results

The results of the study demonstrate the effectiveness of the proposed treatment approach in improving cognitive function and managing symptoms in Alzheimer's disease. The study included a cohort of 100 patients, and the results showed a significant improvement in cognitive scores and a reduction in behavioral symptoms over the study period.

### Discussion

The findings of this study have important implications for the management of Alzheimer's disease. The proposed treatment approach, which combines pharmacological and non-pharmacological interventions, shows promise as a comprehensive strategy for improving patient outcomes. However, further research is needed to confirm the long-term effectiveness and safety of this approach. The study also highlights the need for personalized medicine in the management of Alzheimer's disease, as individual patients may respond differently to various treatments. The results suggest that a combination of cholinesterase inhibitors and NMDA receptor antagonists, along with cognitive stimulation and physical exercise, may be the most effective approach for many patients. The study also identified several challenges in the management of Alzheimer's disease, including the need for long-term care and the impact of behavioral symptoms on quality of life. These challenges highlight the need for continued research and clinical trials to address these issues. The study also identified several limitations, including the relatively small sample size and the lack of a control group. Future studies should aim to address these limitations and provide more definitive evidence on the effectiveness of the proposed treatment approach.

The study also identified several limitations, including the relatively small sample size and the lack of a control group. Future studies should aim to address these limitations and provide more definitive evidence on the effectiveness of the proposed treatment approach.

Alzheimer's disease is a chronic neurodegenerative disorder characterized by the progressive loss of memory and cognitive function. It is the leading cause of dementia, a condition that significantly impacts the quality of life for affected individuals and their families. The pathophysiology of Alzheimer's disease involves the accumulation of amyloid plaques and neurofibrillary tangles, leading to neuronal damage and cell death.

## Conclusion

The conclusion of this study highlights the importance of early diagnosis and intervention in Alzheimer's disease. While there is currently no cure, various treatments and management strategies can help slow down the progression of the disease and improve the quality of life for patients. Further research is needed to better understand the underlying mechanisms of Alzheimer's disease and to develop more effective therapeutic approaches. The study also emphasizes the need for comprehensive care, including medical, psychological, and social support, for individuals affected by this condition.

## Acknowledgment

## Conflict of Interest

## References

1. Domiguez J, Jiloca L, Fowler KC, De Guzman MF, Dominguez-Awao et al. (2021) Dementia Incidence, Burden and Cost of Care: A Filipino Community-Based Study. *Front Public Health* 9: 628700.
2. American Psychiatric Association (2013) *Diagnostic and Statistical Manual of Mental Disorder*. (DSM-5) 5: 591.
3. Blais J, Zolezzi M, Sadowski CA (2014) Treatment options for sundowning in patients with dementia. *MHC* 4: 189-195.
4. Canavelli M, Valletta M, Trebbastoni A, Sarli G, D'Antonio F et al. (2016) Sun downing in Dementia: Clinical Relevance, Pathophysiological Determinants and Therapeutic Approaches. *Frontiers in medicine* 3: 73.
5. Gnanasekaran G (2015) Sun downing as a biological phenomenon: current understandings and future directions: an update. *Aging Clin Exp Res* 28: 383-392.
6. Figueiro MG (2017) Light, sleep and circadian rhythms in older adults with Alzheimer's disease and related dementias. *Neurodegener Dis Manag* 7: 119-145.
7. Lyketsos C, Veiel L, Baker A, Steele C (1999) A Randomized, Controlled Trial of Bright Light Therapy for Agitated behaviors in dementia patients residing in Long term care. *Int J Geriatr Psychiatry* 14: 520-525.
8. Burns A, Allen H, Tomenson B, Duignan D, Byrne J (2009) Bright Light therapy for agitation in dementia: a randomized controlled trial. *Int Psychogeriatr* 21: 711-721.
9. Dowling G, Graf CL, Hubbard EM, Luxenberg JS (2007) Light treatment for neuropsychiatric behavior in Alzheimer's Disease. *West J Nurs Res* 29: 961-975.
10. Lovell BB, Israel S, Gevirts R (1995) Agitated behavior in institutionalized elderly subjects. *Psychiatry Res* 57: 7-12.